Treatment
Drug: Adjuvant therapy clinical trials
We’re tracking 118 recruiting studies that include Drug: Adjuvant therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT07441226RecruitingPhase 2
Stem cells for advanced COPD treatment
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
Jakarta, Jakarta Special Capital RegionAges 40–75 - NCT07492615RecruitingPhase 2
Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07590024RecruitingPhase 3
Personalized Cancer Treatment Guidance for Nasopharyngeal Cancer
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
Beijing, Beijing MunicipalityAges 18–65 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07632118RecruitingPhase 3
Radiation and chemotherapy after pancreatic cancer surgery
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT06405269Enrolling by invitation
How breast cancer treatment affects cholesterol in young women
This study looks at how chemotherapy, hormone therapy, or targeted therapy affects cholesterol levels in younger women with early-stage breast cancer that can be removed with surgery. It may help doctors understand how to better manage heart health during cancer treatment.
Beijing, Beijing MunicipalityAges 18–40 - NCT06306612Recruiting
Surgery plus hormone therapy for advanced prostate cancer
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06341894RecruitingPhase 2
Dalpiciclib and hormone therapy for early breast cancer
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Nanjing, JiangsuAges 18–75 - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT06552091Recruiting
Digital self-hypnosis for hot flashes from hormone therapy
This trial tests a guided digital self-hypnosis program to help reduce hot flashes caused by hormone therapy for breast cancer. It aims to see if it can make hot flashes less frequent and bothersome.
Vandœuvre-lès-NancyAges 18 years+ - NCT04688801Recruiting
Chemo plus immunotherapy after surgery for esophageal cancer
This study looks at adding immunotherapy to standard chemotherapy after surgery for certain esophageal or EG-junction cancers. It may help lower the chance the cancer comes back, for people whose cancer can be fully removed.
Jinan, ShandongAges 25–80 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT06587789Recruiting
Ribociclib plus hormone therapy for high-risk breast cancer
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT06792149Recruiting
Guiding gastric cancer treatment with 3D bioprinting
This trial uses a 3D-printed model of your tumor to predict which drugs will work best for your gastric cancer. It aims to make treatment more personalized and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07541079RecruitingPhase 3
Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Fountain Valley, CaliforniaAges 18 years+ - NCT05541016RecruitingPhase 2
Personalized lower-dose radiation for HPV-related throat cancer
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
Scottsdale, ArizonaAges 18 years+ - NCT05797467RecruitingPhase 3
After-surgery chemo plus targeted therapy for colon cancer
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
Guangzhou, GuangdongAges 18–75 - NCT07604909RecruitingPhase 2
Serplulimab plus chemotherapy for early-relapsed colorectal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
ShanghaiAges 18 years+
Common questions
- Are there clinical trials studying Drug: Adjuvant therapy?
- Yes. Clin2 currently lists 118 recruiting studies that include Drug: Adjuvant therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Drug: Adjuvant therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Drug: Adjuvant therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Drug: Adjuvant therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.